Timothy M. Mayleben - 13 May 2021 Form 4 Insider Report for Landos Biopharma, Inc.

Role
Director
Signature
/s/ Eric W. Blanchard, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
13 May 2021
Net transactions value
$0
Form type
4
Filing time
17 May 2021, 17:57:49 UTC
Next filing
21 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LABP Stock Option (right to buy) Award $0 +36,000 $0.000000 36,000 13 May 2021 Common Stock 36,000 $10.20 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying this option will vest and become exercisable in 36 equal monthly installments beginning on May 13, 2021, subject to the Reporting Person's continuous service with the Issuer on each such date.